Sphere Fluidics Appoints Edward Rayner as Non-Executive Director
April 17 2024 - 4:18AM
Business Wire
Ed Rayner joins Sphere Fluidics as new board
member to strengthen the Company’s strategic vision and ambition
for commercial growth
Sphere Fluidics, a leading provider of innovative
microfluidics-based solutions for single-cell analysis and
isolation, today announced the appointment of Ed Rayner to its
Board of Directors as a Non-Executive Director. Leveraging
extensive experience in fundraising and investment within the life
sciences and technology sectors, Ed’s appointment will strengthen
the Company’s strategic vision as it progresses ambitious plans for
future growth and commercial success.
Throughout his career, Ed has held a number of key analyst and
portfolio management positions at leading research-led investment
firms, including AMP Capital, Alliance Bernstein, UBS Asset
Management and JP Morgan Investment Management. He has worked
across a broad range of sectors, including healthcare and
technology, in addition to managing equity portfolios, running a
research team, and launching a small companies fund. More recently,
Ed worked in biotech venture capital at Arix Bioscience and, in
that role, represented the fund as an NED for various Life Sciences
companies, including Pharmaxis, Depixus, and Simbec Orion Group. In
his current role as a Healthcare Consultant for investment bank
Panmure Gordon, he works with private Life Sciences companies to
raise capital. He has an MA in Chemistry and MSc in Management from
Oxford University, and is a Chartered Financial Analyst.
Dr. Frank F. Craig, CEO, Sphere Fluidics, commented:
“We’re very pleased that Ed has joined the Sphere Fluidics Board.
He has an excellent international investment banking background
blended with experience from leading investment funds. His acumen
will help us map out our growth plans, competitive positioning and
a strong exit.”
Ed Rayner, Non-Executive Board Director, Sphere Fluidics,
added: “I’m excited to join the Sphere Fluidics Board to
support the Company as it accelerates its commercial roll out. The
multi-disciplinary science and engineering teams have developed a
ground-breaking suite of products that can make a huge difference
to the success of drug development programmes.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417202852/en/
Zyme Communications Lily Jeffery Tel: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com